News

Opinion
Zacks Investment Research on MSN2dOpinion
Top Analyst Reports for Alphabet, Bank of America & Roche
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Bank of ...
Harald Reiso MD, specialist in general medicine and public health, and advisor at the National Advisory Unit for Tick-Borne Diseases ... he has received fees from Roche (distributor of Vabysmo) for ...
Last week, the company announced a 2.04bn yuan ($282m) investment to build a new production site in Shanghai for its eye drug Vabysmo (faricimab). That facility is expected to be completed by 2029 and ...
Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG BAYRY ... for some time now due to competition from Vabysmo. We note that Vabysmo's uptake has been outstanding.
Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the ...
while its Diagnostics unit brought in CHF 3.5B, mostly unchanged from last year. RHHBY’s multiple sclerosis therapy Ocrevus, eye therapy Vabysmo, and hemophilia therapy Hemlibra drove the pharma ...
Vabysmo, Phesgo Fuel Roche (RHHBY), Pipeline ... back of its robust Battery Management System solutions. Uniform Rental Unit to Aid Cintas (CTAS) amid Rising Costs Per the Zacks analyst, Cintas ...
Vabysmo, Phesgo Fuel Roche (RHHBY), Pipeline ... Per the Zacks analyst, Cintas' Uniform Rental and Facility Services unit is driven by the penetration of additional products and services into ...
“Our growing commercial royalty portfolio of six assets is supported by VABYSMO® (faricimab), OJEMDA ... Bioscience's Biopharma Solutions business unit. Daré Bioscience XOMA Royalty ...
Vabysmo pre-filled syringe now also approved ... so there were more costs coming from other units into SG&A. Diabetes Care is one element that we integrated, just to mention example here, that's ...
The pharmaceuticals unit continues to be the biggest money-maker, earning nearly $50.9 billion last year. Key growth drivers were Vabysmo, Phesgo, Ocrevus and Hemlibra, which together collected 16.9 ...